A 49-kD protein was specifically detected in hematopoietic organs by Western blotting with a novel mouse monoclonal antibody ( 8 9 2 ) raised against stromal cells. The protein was found in the immunizing cells using a sensitive method. However, its detection in the bone marrow by the B92 antibody seemed to stem from the abundance of p49 in immature cells of the myeloid lineage. Study of the bone marrow following in vivo irradiation or 5-fluorouracil (5-FU) treatment, in vitro culture with differentiation-inducing factors and long-term culture, and cell sorting all pointed in the same direction: the protein was found in early myeloid cells and in hematopoietic precursor cells. These results were in accordance with the specific presence of p49 in primary radi-EMATOPOIETIC CELLS are derived from a common stem-cell population that gives rise to a series of lineage-restricted progenitors. Myeloid progenitor cells are endowed with the potential to differentiate into granulocytes and macrophages. Much is known about the cytokines that induce growth of myeloid progenitor cells,' and recent studies have unraveled some cellular regulatory proteins that control transcription and play a role in lineage determination.* Dramatic phenotypic changes occur in cells during differentiation, although these are often accompanied by only a few changes in the expression of nuclear proteins? This enabled the identification of proteins that play a role in lineage-specific differentiation. Myeloid cell nuclear differentiation antigen (MNDA) is found in leukemia cell lines with a relatively more differentiated phenotype. MNDA is detectable in the early stages of granulocyte/monocyte differentiation and is maintained in mature granulocytes and monocytes.435 The zinc finger transcription factor, Egr-l, is expressed upon induction of macrophage differentiation and its expression deprives HL-60 cells of the option to differentiate into granulocytes.6 Abnormal expression of the Evi-l zinc finger gene in a myeloid cell line blocked the ability of the cells to differentiate into granulocytes. The activation of this gene by retroviral insertions is thought to contribute to the induction of myeloid leukemia.' A number of other gene products that are preferentially expressed in myeloid cells have been identified. MZF-1 is a myeloid cell-specific zinc finger and MyNF-1 is a myeloid cell-restricted transcription factor that binds to a site in the promoter region of the myeloid-specific myeloperoxidase gene." Molecules that are restricted to a particular hematopoietic lineage and are modulated during differentiation should therefore be expected to take part in the regulation of differentiation.
A 49-kD protein was specifically detected in hematopoietic organs by Western blotting with a novel mouse monoclonal antibody ( 8 9 2 ) raised against stromal cells. The protein was found in the immunizing cells using a sensitive method. However, its detection in the bone marrow by the B92 antibody seemed to stem from the abundance of p49 in immature cells of the myeloid lineage. Study of the bone marrow following in vivo irradiation or 5-fluorouracil (5-FU) treatment, in vitro culture with differentiation-inducing factors and long-term culture, and cell sorting all pointed in the same direction: the protein was found in early myeloid cells and in hematopoietic precursor cells. These results were in accordance with the specific presence of p49 in primary radi-EMATOPOIETIC CELLS are derived from a common stem-cell population that gives rise to a series of lineage-restricted progenitors. Myeloid progenitor cells are endowed with the potential to differentiate into granulocytes and macrophages. Much is known about the cytokines that induce growth of myeloid progenitor cells,' and recent studies have unraveled some cellular regulatory proteins that control transcription and play a role in lineage determination.* Dramatic phenotypic changes occur in cells during differentiation, although these are often accompanied by only a few changes in the expression of nuclear proteins? This enabled the identification of proteins that play a role in lineage-specific differentiation. Myeloid cell nuclear differentiation antigen (MNDA) is found in leukemia cell lines with a relatively more differentiated phenotype. MNDA is detectable in the early stages of granulocyte/monocyte differentiation and is maintained in mature granulocytes and monocytes. 435 The zinc finger transcription factor, Egr-l, is expressed upon induction of macrophage differentiation and its expression deprives HL-60 cells of the option to differentiate into granulocytes.6 Abnormal expression of the Evi-l zinc finger gene in a myeloid cell line blocked the ability of the cells to differentiate into granulocytes. The activation of this gene by retroviral insertions is thought to contribute to the induction of myeloid leukemia.' A number of other gene products that are preferentially expressed in myeloid cells have been identified. MZF-1 is a myeloid cell-specific zinc finger and MyNF-1 is a myeloid cell-restricted transcription factor that binds to a site in the promoter region of the myeloid-specific myeloperoxidase gene." Molecules that are restricted to a particular hematopoietic lineage and are modulated during differentiation should therefore be expected to take part in the regulation of differentiation.
We derived a monoclonal antibody (B92) that recognizes a 49-kD protein specifically detectable in hematopoietic organs.
Analysis of cellular and temporal expression of this protein showed that it is a nuclear protein found in hematopoietic precursor cells and in early stages of the myeloid differentiation series.
MATERIALS AND METHODS

H
Bone marrow and peripheral blood cells. Mouse bone marrow cells were obtained from the femur and tibia of 6-to 8-week-old ation-induced myeloid leukemia and its absence in spontaneous B lymphoma. Immunofluorescent staining using B92 antibody detected a nuclear antigen forming a dotted pattern in early myeloid cells and day 12 colony-forming unitsspleen (CFU-S). Nuclear localization of p49 was further demonstrated by subcellular fractionation followed by Western blotting. We thus identified a nuclear protein that within the hematopoietic population is detected in hematopoietic precursor cells, predominates in early myeloid cells, and is reduced following differentiation. These properties imply that p49 might be involved in the regulation of hematopoietic cell growth or differentiation.
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female BALBK mice or 8-to 12-week-old female mice of the same strain injected intravenously with 150 m a g body weight 5-fluorouracil (5-FU). Eight-week-old (Balblc X DBN2) F1 mice were treated with 6 Cy "CO total-body irradiation. Bone marrow cells were removed aseptically by flushing culture medium through the marrow cavity using a l-mL syringe fitted with a 27-gauge needle. Human blood was obtained from a healthy volunteer. Human and mouse peripheral blood cells were collected in the presence of anticoagulants and treated with hypotonic buffer to remove erythrocytes. For morphologic evaluation, cells obtained directly from animals or following culture (see below) were centrifuged for 5 minutes at 800 rpm in a cytocentrifuge (Shandon, London, UK) onto glass slides, and fixed and stained with May-Griinwald and Gum's Giemsa solution (Reidel-deHaen, Seelze, Germany). Cells were distinguished on the basis of standard morphologic criteria.
Bone marrow cell cultures. Primary bone marrow cells were seeded in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Beth Haemek, Beth Haemek, Israel) either in the presence or absence of cytokines. The cells were retrieved on the indicated days and tested for p49 expression. Long-term bone marrow cultures supported by the stromal cell clone, 14F1.1,''"3 were performed as previously de~cribed.'~ Cytokines. Purified human recombinant granulocyte colonystimulating factor (G-CSF) was kindly provided by Dr S. Gillis (Immunex Corp. Seattle, WA). Macrophage (M)-CSF was purchased from Genzyme Corp (Cambridge, MA). D9 high-conditioned mediumI4 was used as a source of interleukin (IL)-3 and IL-4. Conditioned medium containing recombinant mouse IL-3 was obtained 0.01% NaN3 and 0.5% bovine serum albumin, and subsequently incubated with E R -M P 2 F (fluorescein isothiocyanate)Is and streptavidine-conjugated R-phycoerythrin. Washing buffer was used for all dilutions. All incubations were performed for 30 minutes at 0°C. Cells were sorted on a FACS Vantage using a single-argon ion laser tuned at 488 nm (100 mW). Bone marrow cells were stained with anti-Gr-l antibodies followed by goat antimouse FluorX antibodies and sorted on a FACStafLUS (Becton Dickinson, Mountain View, CA).
Immunoblot analysis. Immunoblot analysis of tissue and cell lysates was performed as previously described.'6 Tissues were lysed for 2 hours in ice-cold 50 mmoVL Tris hydrochloride, pH 7.4, containing 1% Nonidet P 4 0 (NP-40), 150 mmol/L NaCI, 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), and 3 pg/ mL aprotinin. Protein extracts (50 pg per lane) were loaded onto 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). SDS-PAGE analysis was performed on 0.75-mm slab gels according to the method of Laemmli." After electrophoresis, proteins were transferred to nitrocellulose filters (Schleicher & Schuell, Dassel, Germany) and the filters were incubated overnight at 4°C with 3% bovine serum albumin. The filters were then incubated with the indicated monoclonal antibody for 2 hours at room temperature and were washed three times with Tris-buffered saline containing 0.1% Tween (TBST). lmmunoblots were developed by incubation with iodinated AffiniPure rabbit antimouse IgG, F(ab')2 fragment (Jackson, West Grove, PA). Autoradiography was performed using Kodak (Eastman Kodak, Rochester, NY) X-OMAT film at -70°C. Intensity of the band was evaluated using a 1300A computing densitometer (Molecular Dynamics, Sunnyvale, CA).
Immunoprecipitation. Cell lysates were clarified by centrifugation at 15,000g for 10 minutes at 4°C. The resulting supernatants were precleared with protein A-Sepharose (40 p L 50% slurry), and were immunoprecipitated at 4°C with 20 pg B92 monoclonal antibody and protein A-Sepharose (40 pL 50% slurry). lmmunoprecipitates were washed four times with cold SNNTJ? buffer (5% sucrose, 1% NP40,500 mmol/L NaCI, 50 mmoVL Tris, pH 7.4, and 5 mmoU L EDTA) and eluted by boiling in SDS sample buffer (5% vollvol glycerol, 2% wt/vol SDS, 62.5 mmol/L Tris hydrochloride, pH 6.8, 2% vol/vol P-mercaptoethanol, and 0.01% wt/vol bromophenol blue). Samples were analyzed using 10% SDS-PAGE.
Subcellular fractionation of bone marrow cells. Two different methods were used to fractionate cell components. In the first method, bone marrow cells were pretreated with hypotonic buffer to remove erythrocytes. The cells were washed three times with icecold PBS and homogenized in IO mmom Tris, pH 7.4, supplemented with 140 mmol/L NaCI, 3 mmol/L MgClz, and 0.5 mmoll L PMSF using a Dounce glass homogenizer. The resulting pellet was observed in a phase-contrast microscope to verify the presence of free nuclei. The extract was centrifuged at 200g for 10 minutes at 4°C to pellet the nuclei. The supernatant was clarified by centrifugation at 15,000g for 30 minutes at 4°C to yield final cytosolic supernatant and crude membrane pellet. Pellet was resuspended in the above buffer and then overlaid on a two-layer sucrose gradient (20% and 35%). After centrifugation at 20,000 rpm for 60 minutes, membrane proteins were removed from the interphase of the gradient and washed with the same buffer by centrifugation at 40,000 rpm for 20 minutes at 4°C. The pellet was dissolved in 10 mmoVL Tris, pH 7.4, 140 mrnoVL NaCI, 3 rnmol/L MgClz, 0.5 mmolL PMSF, ~p12bt0 , IS washed in phosphate-buffered saline (PBS) containing 0.1% SDS, and 1% NP40. This method was used in experiments detailed below. An alternative method was used essentially as previously reported.'* Antibodies. Anti-Gr-l mouse monoclonal antibody was provided by Dr Alpha Peled (Weizmann Institute of Science). Fluorophore antibodies used were donkey antimouse-FiTC (Jackson) and goat antimouse-FluorX (BDS, Pittsburgh, PA). Rabbit polyclonal antibody against CEBPa was generously provided by Dr S.L. McKnight (Tularik Inc, San Francisco, CA). B92 and C53 monoclonal antibodies were prepared in our laboratory by immunizing mice with the 14Fl.1, Balblc mouse bone marrow-derived stromal cell clone. Ten 6-to 8-week-old male C57BL/6J mice received subcutaneous injections of 14Fl.l cells, the first with complete Freund's adjuvant and the following two with incomplete Freund's adjuvant, and in four additional injections, only cells were inoculated. Spleen cells of immunized mice were fused with the NSll murine myeloma cell line according to the method of Kohler and Milstein." Radioimmunoassay was used to screen hybridomas secreting antibodies that react with the immunizing 14Fl.l cell. The B92 hybridoma was chosen because it produced the strongest signal with 14Fl.l cells in radioimmunoassay. The hybridoma was recloned several times by limiting dilutions. For large-scale production of the B92 monoclonal antibody, hybridoma cells were maintained in a bioreactor system in serum-free medium with addition of 0. I %J casein hydrolysate as previously described." The antibody was purified using a Poros (Framingham, MA) protein A high-performance liquid chromatography column. C53 monoclonal antibody similarly produced served as a control. since it did not react with nuclear antigens.
Immunocytochemistry. Cells were fixed for 2 minutes in 3% paraformaldehyde with 0.5% Triton X-100, and then for an additional 20 minutes in 3% paraformaldehyde. After washing and blocking in 5% bovine serum albumin, cells were stained with B92 and then with donkey antimouse-FITC antibody for 30 minutes each. Hoechst or "antifade" (as indicated) served as counter-nuclear staining.
Tumors. Acute myeloid leukemia (AML) was induced in SJL/J mice (Jackson Laboratories, Bar Harbor, ME) by total-body sublethal irradiation (300 rad), followed 1 to 3 hours later by subcutaneous inoculation with 0.5 mg dexamethasone*' (Teva, Petach Tikva, lsrael). The same mouse strain develops spontaneous reticulum-cell neoplasms type B (RCNB).** Ajiniry protein purification. The B92 monoclonal antibodyconjugated affinity column was prepared as previously described" and used to partially purify p49.
RESULTS
B92 monoclonal antibody recognizes a 49-kD protein that
is predominantly found in hematopoietic tissues. The B92 hybridoma was obtained by immunization with cell lysates of the 14F1.1 endothelial-adipose stromal cell, and was recloned repeatedly to ensure monoclonality. By Western blotting, this antibody recognized several protein bands in extracts from various tissues (Fig 1) . The most prominent ones were bands at approximately 100 kD and 49 kD. In contrast to all other tissues, in bone marrow the B92 antibody exclusively recognized a 49-M) protein band (Fig 1) . This protein also appeared in other hematopoietic tissues, ie, the spleen and thymus. The 49-kD protein was undetectable in nonhematopoietic organs in which higher-molecular-weight proteins were recognized by the antibody. The 49-M) band was undetectable in cell extracts from primary stromal cultures, as well as from stromal cell lines (not shown). This was peculiar in view of the fact that the B92 antibody was raised against a stromal cell lysate. To increase the sensitivity of detection, we first immunoprecipitated cellular proteins from the 14Fl.l stromal cell clone using B92 monoclonal antibody, and then immunoblotted the precipitate with the same radiolabeled monoclonal antibody. This procedure enabled detection of the 49-kD band (Fig 2) that was otherwise invisible. Thus, stromal cells expressed the 49-kD protein, although in direct immunoblotting, the amount of the protein was below the detection level. The 49-kD band detected by B92 antibody in bone marrow extracts was therefore probably from hematopoietic cells rather than from stromal cells. In bone marrow extracts from irradiated mice, p49 disappeared at day 2 posttreatment and returned to basal levels on day 9, when the marrow is repopulated with hematopoietic cells (Fig 3A) . In bone marrow of mice treated with 5-FU, p49 did not disappear at day 2 (Fig l) , although it was decreased and barely detectable at day 4 ( Fig 3B) . It reappeared as the marrow was repopulated with hematopoietic cells (days 9 to 14) (Fig 3B) . The effect of 5-FU on bone marrow cellularity in our experiments was identical to that previously a decline to 7% of the original cell number occurred at day 4 posttreatment, and an increase at day 14 to about 77% of the original. (Fig 2) , whereas p49 antigen persisted at day 2 post-5-FU (Fig 3B) . This could imply that cells contributing to the signal were of a relatively immature stage. To further examine this possibility, we studied p49 during hematopoietic cell differentiation in vitro. Bone marrow cells were seeded in liquid cultures supplemented with either M-CSF, recombinant (r) IL-3, medium conditioned by a T-cell clone containing various cytokines (predominantly IL-3 and IL-4), or rG-CSF. M-CSF induced accumulation of macrophages that were devoid of Od 2d 4d 9d 14d B - 
-
any p49 (Fig 4A) . The decline in intensity of the p49 signal was more rapid in M-CSF-induced cultures than in unstimulated control cultures. Mast cells accumulating in day 4 cultures stimulated with conditioned medium containing mainly IL-3 and IL-4 were also negative (Fig 4B) . IL-3 by itself had a less pronounced effect on detectability of the p49 protein, but again after 4 days in culture, a reduction in intensity of the 49-kD band occurred (Fig 4C) . By contrast, in bone marrow cultures stimulated with 10 or 50 ng/mL G-CSF, the p49-kD band intensified at day 4 of culture ( Fig  4D) . Morphologic examination showed that these cultures contained a combination of myeloid blast cells and mature granulocytes. In sorted populations of hone marrow cells, p49 is conjned to earlv myeloid cells and hematopoietic precursors. The above results suggested that early myeloid cells might be the source of the p49 protein. To further investigate this possibility, bone marrow cells were fractionated by FACS sorting into the subpopulations detailed in Fig 5. Sorting was performed using the monoclonal antibody, ER-MP12, that defines a novel antigen on stem cells and is differentially expressed in various stem-cell subsets, and the ER-MP20 (anti-Ly-6C) antibody." The sorted populations were analyzed by Western blotting with the B92 monoclonal antibody. In fractions 2 and 5 corresponding to erythroblasts and lymphocytes, respectively, no p49 signal was observed (Fig 5) . As further shown in the figure, p49 was found in fractions 3,4,6, and 7. Fraction 6 consisted of hematopoietic precursor cells and lymphocytes, whereas among fractions 3, 4, and 7 the common denominator was the presence of early granulocytes (Fig 5) . The high-molecular-weight bands recognized by B92 antibody in the spleen and thymus, 
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. 5 as well as in nonhematopoietic organs, become apparent in bone marrow after fractionation (fractions 5 and 6, Fig 5) . In a second sorting, hematopoietic progenitors in a fraction containing 80% blasts were compared with a fraction containing 91% mature granulocytes. The calculated relative amount of p49 in the progenitor cell fraction was 34.3-fold higher than that in the granulocyte fraction (not shown). In addition, p49 was undetectable in cells obtained from mouse and human peripheral blood treated with hypotonic buffer to remove erythrocytes (Fig 2) and in blood samples before erythrocyte removal (not shown). It is therefore concluded that p49 resides in early granulocytic cells and primitive hematopoietic precursors and is undetectable in erythroblasts, erythrocytes, the bulk of lymphocytes, macrophages, and mast cells.
p49 is found in radiation-induced AML and is absent from spontaneous B lymphoma cells of the SJUJ mouse strain. Leukemias are relatively homogeneous populations often representing distinct stages in hematopoietic differentiation. Radiation-and dexamethasone-induced myeloid leukemia in SJWJ mice is an immature blast-cell disease." This mouse strain also develops spontaneous RCNB (B lymphoma)?* We compared these two malignant populations with respect to p49. Consistent with the presence of p49 in early bone marrow myeloid cells, we found p49 in AML blasts obtained from primary and first-passage tumors and from the spleen and lymph nodes of diseased animals. In fact, the spleen of leukemic SJL/J mice had an exclusive p49 band detectable by the B92 antibody, a pattern identical to that of bone marrow from normal animals and distinct from that of normal spleen and lymph nodes (Fig 6) . By contrast, RCNB did not exhibit p49, but alternatively showed the highermolecular-weight bands recognized by B92 antibody. This finding is in concordance with the presence of similar highmolecular-weight bands in extracts prepared from lymphocytes in fraction 5 (Fig 5) , and those found in extracts of normal thymus and spleen in which lymphoid cells predominate. In sharp contrast to primary tumors, established cultured cell lines of myelogenous leukemia or lymphoma did not show any predominant p49 band. Whether the expression of this protein is downregulated upon culture or the encoding gene is mutated remains to be determined.
Human myelogenous leukemias express a 42-kD transcription factor, C/EBPa,'" in a manner reminiscent of that described here for p49. However, the B92 antibody did not recognize C/EBPa in liver nuclear extract, and antibodies to C/EBPa did not recognize partially purified p49 (not shown).
p49 is a nuclear protein. Bone marrow cells examined for expression of B92 antigen show a bright granular nuclear staining in mononuclear cells and an absence of staining in mature segmented granulocytes (Fig 7A) . FACS-sorted Grl-positive bone marrow cells, consisting primarily of various stages of differentiation of the myeloid series, showed specific staining of myeloblasts and myelocytes and lack of staining of mature cell forms (Fig 7D) . Among FACS-sorted WGAbnsh' cells consisting of 60% to 100% colony-forming units-spleen (CFU-S) day 8 and CFU-S day 12,97% showed fine granular nuclear staining (Fig 8A) . The nuclei of blastlike cells, possibly myeloblasts, in the WGAmediumnow fraction had a multitude of bright fluorescent grains (Fig 8B) .
To further substantiate the subcellular localization of p49 in bone marrow cells, two methods of fractionation were used and the fractions were tested by Western blotting. The two methods yielded identical results: p49 was, found in the nuclear fraction, the cytoplasmic fraction showed a weak band, and the membrane fraction was negative (Fig 9) .
DISCUSSION
A variety of proteins that are modulated during myeloid differentiation have been described. Many of those wellcharacterized are lineage-specific and are upregulated during induction of differentiation. MNDAP.s272X CD1 8,29 and CD 1 I b are expressed at the highest levels in mature myeloid cells." We describe here a nuclear protein that, in contrast to the above, is characteristic of early undifferentiated cells and is not found in mature granulocytes or other mature hematopoietic cells. It is of interest to study p49 further, since its restriction to early stages of differentiation may imply a role in the maintenance of the immature, renewing phenotype.
p49 was detected with the B92 antibody. This monoclonal antibody was obtained as part of an effort to characterize a series of stromal cell lines derived in our laboratory, representing phenotypically distinct subtypes."""" One of these, an endothelial-adipose cell line (14Fl.l), was found to have For personal use only. on August 30, 2017. by guest www.bloodjournal.org From band detected in various tissues by the B92 antibody to p49 is the subject of further investigation.
Induction of terminal differentiation using a mixture of cytokines, rIL-3, or M-CSF resulted in reduction of p49. Apparently, differentiation of bone marrow cells to macrophages or mast cells caused elimination of p49. On the other hand, G-CSF at 10 or 50 ng/mL caused an accumulation of early myeloid cells within 4 days of culture and allowed in vitro persistence of p49. This, as well as the finding that immature myeloid cells obtained from within adherent layers of long-term cultures harbored p49 (not shown), suggested that this protein originates from early myeloid cells.
The results of FACS fractionation of the bone marrow to its major subpopulations supported this conclusion. p49 was found in FACS-sorted cell fractions containing early myeloid cells or progenitor cells only.
An expression pattern that is partially similar to that described here for p49 has been reported for a few proteins. NF-jun (55-and 1 2 5 -0 protein) is expressed in human myeloid leukemia cells and is absent from mature granuloc y t e~.~~ The myeloid zinc finger gene, MZF-1, encodes a 485-amino acid protein, the expression of which increases during differentiation in human myeloid leukemia.899 The homeobox genes, HB9 and HB24, are expressed in CD34-positive cells. However, in contrast to p49, these genes? as well as c-myb proto-oncogene that encodes a transcription regulating DNA-binding ~rotein,~'-~' are expressed in lymphocytes. An additional gene expressed in early myeloid cells is PU. 1, a member of the ETS oncogene family. Unlike p49, this gene is found also in early erythroid and megakaryoid cells:' macrophages, and B and is essential for
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From normal development of multiple hematopoietic lineagesw A striking similarity was found between the expression of p49 and one member of the CCAAT/enhancer binding protein (CIEBP) family. 26 The C/EBPa protein was found to be specifically expressed by early myeloid cells of both normal and malignant origin. As the differentiation process commenced, a decline in expression of CEBPa was observed, and mature myeloid cells were almost devoid of this protein.
In nine of 10 human AML patients CEBPa was expressed, whereas in seven ALL cases no expression was observed. 26 This correlates well with our results indicating that in mouse myeloblastic leukemia, each tumor (to date, >60 were tested) harbored $9, as compared with the B-cell neoplasms, among which none had this protein. However, this similarity seems coincidental, since B92 antibody did not recognize a protein in liver nuclear extract enriched for C/ EBPa, and an antibody to CIEBPa did not recognize partially purified p49, whereas it reacted strongly with the liver nuclear extract (results not shown). Thus, p49 does not seem to be the mouse counterpart of the rat and human CEBPa gene products. The similar differentiation stage-related expression of CIEBPa and p49 proteins suggests that their genes might be regulated by a common mechanism.
The localization of p49 was investigated by subcellular fractionation of bone marrow cells followed by Western blotting. The 49-kD protein was found mostly in the nuclear fraction. The small signal found in the cytoplasm could result either from the presence of some of the protein in the cytoplasm or from nuclear contamination in the cytoplasmic preparation, because of the limitation of accuracy of the fractionation method used. Nuclear localization was also demonstrated by immunofluorescence of mouse bone marrow and thymus cells using the B92 antibody. This antibody produced granular staining, predominantly in the nuclei of young myeloid cells and lymphoid cells. Staining of thymocytes showed that the antibody reacted with a nuclear antigen producing granular staining (not shown). This was probably due to the 100-kD protein expressed by lymphoid cells (Fig   5, lane R5) . Examination of sorted granulocytes (including all stages of maturation) clearly showed nuclear staining of immature cells only (Fig 7D) . Moreover, FACS-sorted immature granulocytes produced a p49 signal in Western blotting that was 34.3-fold higher than that produced by mature granulocytes. Finally, granular nuclear staining was observed in FACS-sorted day 12 CFU-S. Some transcription factors have been shown by knockout experiments to be essential for hematopoiesis in vivo. Loss of GATA-2, as an example, caused broad hematopoietic defi~it.~'.~' Nuclear localization and confinement of p49 to the early stages of hematopoietic merentiation may imply that this protein is involved in maintenance of the unmeEntiated cell state. Identification of the gene encoding this protein will provide the tools for studying its possible role in hematopoiesis.
